UY31394A1 - Anticuerpos que se unen a il-4y/o il-13 y sus usos - Google Patents

Anticuerpos que se unen a il-4y/o il-13 y sus usos

Info

Publication number
UY31394A1
UY31394A1 UY31394A UY31394A UY31394A1 UY 31394 A1 UY31394 A1 UY 31394A1 UY 31394 A UY31394 A UY 31394A UY 31394 A UY31394 A UY 31394A UY 31394 A1 UY31394 A1 UY 31394A1
Authority
UY
Uruguay
Prior art keywords
antibodies
join
new
dermatitis
moieties
Prior art date
Application number
UY31394A
Other languages
English (en)
Inventor
Davison Matthew
Kruip Jochen
Li Danxi
Rao Ercole
Vincent Mikol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39313041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31394(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UY31394A1 publication Critical patent/UY31394A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invencion se refiere a nuevos anticuerpos anti-IL-4 y IL-13 humanizados y a fregmentos de los mismos, y a nuevos anticuerpos biespecíficos y fragmentos de los mismos que se unen específicamente a IL-4 y a IL-13. La invencion también incluye usos de los anticuerpos para tratar o prevenir enfermedades o trastornos mediados por IL-4 y/o il-13, incluyendo asma alérgica y dermatitis.
UY31394A 2007-10-15 2008-10-15 Anticuerpos que se unen a il-4y/o il-13 y sus usos UY31394A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07291259A EP2050764A1 (en) 2007-10-15 2007-10-15 Novel polyvalent bispecific antibody format and uses thereof
US3712808P 2008-03-17 2008-03-17

Publications (1)

Publication Number Publication Date
UY31394A1 true UY31394A1 (es) 2009-05-29

Family

ID=39313041

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31394A UY31394A1 (es) 2007-10-15 2008-10-15 Anticuerpos que se unen a il-4y/o il-13 y sus usos

Country Status (43)

Country Link
US (17) US8388965B2 (es)
EP (12) EP2050764A1 (es)
JP (5) JP5858616B2 (es)
KR (5) KR101681909B1 (es)
CN (3) CN101827863B (es)
AR (3) AR068861A1 (es)
AU (5) AU2008312655B2 (es)
BR (1) BRPI0818677B8 (es)
CA (3) CA3015470C (es)
CL (4) CL2008003037A1 (es)
CR (5) CR11337A (es)
CY (5) CY1114987T1 (es)
DK (5) DK2573119T3 (es)
DO (3) DOP2010000109A (es)
ES (5) ES2647872T3 (es)
GT (1) GT201000067A (es)
HN (1) HN2010000710A (es)
HR (5) HRP20140150T1 (es)
HU (4) HUE038556T2 (es)
IL (2) IL205005A (es)
LT (4) LT2574629T (es)
MA (1) MA31838B1 (es)
MX (6) MX354150B (es)
MY (1) MY171214A (es)
NI (7) NI201000406A (es)
NO (2) NO2573121T3 (es)
NZ (3) NZ709353A (es)
PA (1) PA8799001A1 (es)
PE (1) PE20091382A1 (es)
PH (2) PH12013501032B1 (es)
PL (5) PL2205640T3 (es)
PT (5) PT2573121T (es)
RS (5) RS57060B1 (es)
RU (4) RU2580049C2 (es)
SG (4) SG10201913836SA (es)
SI (5) SI2573119T1 (es)
TN (1) TN2010000126A1 (es)
TR (2) TR201802225T4 (es)
TW (4) TWI616206B (es)
UA (2) UA118949C2 (es)
UY (1) UY31394A1 (es)
WO (1) WO2009052081A2 (es)
ZA (1) ZA201002069B (es)

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2009040562A1 (en) 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
GB2468232B (en) * 2007-11-30 2012-10-24 Glaxo Group Ltd Antigen-bindng constructs
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
MX2011001696A (es) * 2008-08-14 2011-03-25 Merck Sharp & Dohme Metodos para purificar anticuerpos usando cromatografia de afinidad con proteina a.
SI2334705T1 (sl) 2008-09-26 2017-05-31 Ucb Biopharma Sprl Biološki produkti
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
CA2757931C (en) 2009-04-07 2019-03-26 Roche Glycart Ag Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
WO2011030107A1 (en) * 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
RU2573915C2 (ru) 2009-09-16 2016-01-27 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применение
GB201000467D0 (en) * 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
FR2958936A1 (fr) 2010-04-14 2011-10-21 Sanofi Aventis Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
WO2012009544A2 (en) * 2010-07-14 2012-01-19 Amgen Inc. Domain insertion immunoglobulin
EP2601298B1 (en) * 2010-08-02 2016-11-30 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
JP2013537415A (ja) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
CN103068847B (zh) 2010-08-24 2019-05-07 罗切格利卡特公司 可活化的双特异性抗体
EP2609111B1 (en) 2010-08-24 2017-11-01 F. Hoffmann-La Roche AG Bispecific antibodies comprising a disulfide stabilized-fv fragment
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CN102675460B (zh) * 2011-02-28 2015-08-19 珠海市丽珠单抗生物技术有限公司 抗肿瘤坏死因子α的人源化抗体
WO2012116927A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
MX341921B (es) 2011-02-28 2016-09-07 Hoffmann La Roche Proteinas de union a antigeno.
EP2686014A1 (en) * 2011-03-16 2014-01-22 Sanofi Uses of a dual v region antibody-like protein
LT3199547T (lt) * 2011-03-28 2021-02-25 Sanofi Antikūnų tipo surišantys baltymai su dviguba sritimi, turintys kryžminę surišimo srities orientaciją
TWI671315B (zh) * 2011-03-28 2019-09-11 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CN107936121B (zh) * 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
SG10201914002RA (en) 2011-08-05 2020-03-30 Regeneron Pharma Humanized universal light chain mice
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
SI2782598T1 (sl) 2011-11-23 2020-12-31 In3Bio Ltd. Rekombinantni proteini in njihove terapevtske uporabe
WO2013103783A1 (en) * 2012-01-04 2013-07-11 Sanofi Us Murine il-13 antibodies
BR112014019579A2 (pt) 2012-02-10 2019-10-15 Genentech, Inc Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
WO2013148232A1 (en) * 2012-03-27 2013-10-03 Genentech, Inc. Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
EP2867254B1 (en) 2012-06-27 2017-10-25 F. Hoffmann-La Roche AG Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
MX354862B (es) 2012-06-27 2018-03-23 Hoffmann La Roche Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
AU2013305945B2 (en) 2012-08-21 2018-07-26 Regeneron Pharmaceuticals Inc. Methods for treating or preventing asthma by administering an IL-4R antagonist
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
LT3366705T (lt) 2012-09-12 2023-07-25 Genzyme Corporation Polipeptidai, turintys fc domeną, kurių glikozilinimas pakeistas ir susilpninta efektorinė funkcija
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
AU2013337644A1 (en) 2012-11-01 2015-05-07 Abbvie Inc. Stable Dual Variable Domain Immunoglobulin protein formulations
JP6109952B2 (ja) 2012-11-01 2017-04-05 アッヴィ・インコーポレイテッド 抗ｖｅｇｆ／ｄｌｌ４二重可変ドメイン免疫グロブリンおよびこれらの使用
MX358321B (es) 2012-11-20 2018-08-14 Sanofi Sa Anticuerpos anti-ceacam5 y usos de los mismos.
PE20151603A1 (es) 2012-12-27 2015-11-20 Sanofi Sa Anticuerpos anti-lamp1 y conjugados anticuerpo farmaco, y usos de estos
EP2970469B1 (en) 2013-03-11 2018-10-03 Genzyme Corporation Hyperglycosylated binding polypeptides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
RU2714733C2 (ru) * 2013-03-15 2020-02-19 Мемориал Слоан-Кеттеринг Кэнсер Сентер Технологии мультимеризации
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CA2903258C (en) * 2013-03-15 2019-11-26 Amgen Inc. Heterodimeric bispecific antibodies
EP2981286A4 (en) * 2013-04-05 2016-08-24 Hoffmann La Roche ANTI-IL-4 ANTIBODIES AND BISPECIFIC ANTIBODIES AND USES THEREOF
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
CA2922912A1 (en) 2013-10-11 2015-04-16 F. Hoffmann-La Roche Ag Multispecific domain exchanged common variable light chain antibodies
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
TN2016000142A1 (en) 2013-10-31 2017-10-06 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers.
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CA3204788A1 (en) * 2013-12-20 2015-06-25 Genentech, Inc. Antibodies comprising an antigen-binding site that specifically binds to two different epitopes and methods of making them
EP2893939A1 (en) 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody
TW201542226A (zh) * 2014-02-12 2015-11-16 Sanofi Sa 抗－ｉｌ－４／抗－ｉｌ－１３雙特異性抗體／聚麩胺酸配製物
JP2017507939A (ja) * 2014-02-21 2017-03-23 ジェネンテック， インコーポレイテッド 抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
WO2015127229A1 (en) * 2014-02-21 2015-08-27 Sanofi Methods for treating or preventing asthma by administering an il-4r antagonist
CA2942769A1 (en) 2014-03-19 2015-09-24 Genzyme Corporation Site-specific glycoengineering of targeting moieties
JP2017510273A (ja) 2014-03-21 2017-04-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 異なる結合特性を示すｖｌ抗原結合タンパク質
KR102601491B1 (ko) 2014-03-21 2023-11-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
TW201628647A (zh) 2014-06-27 2016-08-16 賽諾菲公司 抗－ｉｌ４－ｉｌ１３雙特異性抗體
CN107074948B (zh) 2014-07-11 2022-01-28 根马布股份公司 结合axl的抗体
WO2016044707A1 (en) 2014-09-18 2016-03-24 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
US10064952B2 (en) 2014-10-09 2018-09-04 Genzyme Corporation Glycoengineered antibody drug conjugates
EP3218412A1 (en) 2014-11-14 2017-09-20 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
EP3222637A4 (en) * 2014-11-21 2018-10-31 Astellas Pharma Inc. Novel bispecific antibody format
ES2764111T3 (es) 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
MA40801A1 (fr) 2015-01-23 2018-07-31 Sanofi Sa Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
EP3067062A1 (en) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
CN107430117A (zh) * 2015-03-16 2017-12-01 豪夫迈·罗氏有限公司 检测和定量IL‑13的方法和在诊断和治疗Th2相关疾病中的用途
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
HUE049072T2 (hu) 2015-07-10 2020-09-28 Genmab As AXL-specifikus ellenanyag-drog konjugátumok rák kezelésére
CR20180288A (es) 2015-10-25 2018-09-11 Us Health Proteínas de union triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih
AR106543A1 (es) 2015-11-02 2018-01-24 Netris Pharma Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético
WO2017117384A1 (en) 2015-12-31 2017-07-06 Development Center For Biotechnology Anti-vegfr antibody and uses thereof
US10472422B2 (en) * 2016-01-08 2019-11-12 Abgenomics International Inc. Tetravalent anti-PSGL-1 antibodies and uses thereof
AU2017233121B2 (en) 2016-03-15 2023-12-21 Itabmed (Hk) Limited Multispecific Fab fusion proteins and use thereof
IL262241B1 (en) * 2016-04-13 2024-01-01 Sanofi Sa Trispecific and/or trivalent binding proteins with an arm that has a cross-linking dual variable domain and a traditional FAB antibody arm, the pharmaceutical composition that includes said binding proteins and their uses in the prevention and/or treatment of cancer or inflammatory diseases
FI3443006T3 (fi) * 2016-04-13 2023-10-23 Sanofi Sa Trispesifisiä ja/tai kolmiarvoisia sitojaproteiineja
TW201808336A (zh) 2016-05-11 2018-03-16 賽諾菲公司 用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案
MA45672A (fr) 2016-07-14 2019-05-22 Biontech Ag Anticorps multispécifiques dirigés contre cd40 et cd137
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
CA3034768A1 (en) 2016-08-26 2018-03-01 Sanofi Multispecific antibodies facilitating selective light chain pairing
TW202300515A (zh) 2016-10-20 2023-01-01 法商賽諾菲公司 抗ｃｈｉｋｖ抗體及其用途
SG11201903693QA (en) 2016-11-01 2019-05-30 Genmab Bv Polypeptide variants and uses thereof
WO2018106931A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EA039433B1 (ru) 2017-01-05 2022-01-27 Нетрис Фарма Комбинированное лечение лекарственными средствами, интерферирующими с нетрином-1, и лекарственными средствами, ингибиторами контрольных точек иммуного ответа
US10626169B2 (en) 2017-02-17 2020-04-21 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
JP7304288B2 (ja) 2017-02-17 2023-07-06 サノフイ ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子
KR101961871B1 (ko) * 2017-02-20 2019-07-17 주식회사 와이바이오로직스 신규 다중특이적 결합 단백질
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
MA49259A (fr) 2017-06-07 2020-04-15 Genmab Bv Anticorps thérapeutiques à base d'hexamères d'igg mutées
EP3648757A4 (en) * 2017-07-03 2020-11-25 Development Center for Biotechnology ANTI-VEGFR ANTIBODIES AND USES THEREOF
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
WO2019051204A1 (en) 2017-09-08 2019-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER
EP4249068A3 (en) 2017-10-10 2023-11-22 Sanofi Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
CN109705217B (zh) * 2017-10-25 2020-09-11 北京智仁美博生物科技有限公司 抗il-13抗体及其用途
US11034768B2 (en) 2017-10-30 2021-06-15 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
SG11202006410WA (en) 2018-01-12 2020-08-28 Genzyme Corp Methods for the quantitation of polypeptides
WO2019145455A1 (en) 2018-01-24 2019-08-01 Genmab B.V. Polypeptide variants and uses thereof
KR20200115568A (ko) 2018-01-26 2020-10-07 젠자임 코포레이션 FcRn에 대한 증진된 결합 및 연장된 반감기를 갖는 Fc 변이체
KR20200130363A (ko) * 2018-03-05 2020-11-18 에따블리스망 프랑스와 뒤 상 재조합 단일 쇄 면역글로불린
SG11202008718UA (en) * 2018-03-09 2020-10-29 Brigham & Womens Hospital Inc Combination therapy for cardiovascular diseases
CN112839958A (zh) 2018-05-03 2021-05-25 根马布私人有限公司 抗体变体组合及其用途
WO2019243636A1 (en) 2018-06-22 2019-12-26 Genmab Holding B.V. Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
WO2020012038A1 (en) 2018-07-13 2020-01-16 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
JP2021524276A (ja) 2018-07-13 2021-09-13 ゲンマブ エー／エス Ｃｄ３８抗体のバリアントおよびその使用
KR20210116429A (ko) 2018-10-04 2021-09-27 젠맵 홀딩 비.브이. 이중특이적 항-cd37 항체를 포함하는 제약 조성물
AU2019357467A1 (en) 2018-10-09 2021-05-27 Sanofi Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
AU2019403445A1 (en) 2018-12-21 2021-07-29 Aim Immunotech Inc. Compositions and methods for cancer therapy
CN111514292B (zh) * 2018-12-25 2023-06-20 江苏荃信生物医药股份有限公司 抗人白介素4受体α单克隆抗体的制药用途
AU2020231343A1 (en) 2019-03-06 2021-10-21 Regeneron Pharmaceuticals, Inc. IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer
SG11202109002XA (en) 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
KR20220012894A (ko) 2019-05-24 2022-02-04 사노피 전신 경화증의 치료 방법
EP3753954A1 (en) 2019-06-21 2020-12-23 Université de Franche-Comté Anti-cd123 antibodies, anti-cd123 chimeric antigen receptors and anti-cd123 chimeric antigen receptors t cells
US20230107034A1 (en) 2019-07-16 2023-04-06 The Brigham And Women's Hospital, Inc. Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease
US20210024620A1 (en) 2019-07-25 2021-01-28 Genzyme Corporation Methods of Treating Antibody-Mediated Disorders with FcRn Antagonists
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20230132241A1 (en) 2020-01-15 2023-04-27 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
US20230047809A1 (en) 2020-01-31 2023-02-16 Sanofi Pulmonary delivery of antibodies
CN115515643A (zh) 2020-02-28 2022-12-23 建新公司 用于优化的药物缀合的经修饰的结合多肽
EP4114368A1 (en) 2020-03-03 2023-01-11 Active Biotech AB Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
TW202146463A (zh) 2020-03-05 2021-12-16 法商賽諾菲公司 蛋白酶加工的分子
WO2021185934A1 (en) 2020-03-18 2021-09-23 Genmab A/S Antibodies binding to b7h4
IL297222A (en) 2020-04-24 2022-12-01 Sanofi Sa Antitumor combinations containing conjugates of antibodies to ceacam5 and cetuximab
CA3181000A1 (en) 2020-04-24 2021-10-28 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri
IL297311A (en) 2020-04-24 2022-12-01 Sanofi Sa Antitumor combinations containing conjugates of antibodies to ceacam5 and folfox
KR20230005258A (ko) 2020-04-24 2023-01-09 사노피 항-ceacam5 항체 접합체 및 트리플루리딘 및 티피라실을 함유하는 항종양 병용물
CN114957472B (zh) * 2020-06-22 2023-10-31 南京融捷康生物科技有限公司 抗IL-4Rα的单域抗体以及应用和药物
WO2021263075A1 (en) * 2020-06-26 2021-12-30 St. Jude Children's Research Hospital, Inc. Methods of generating an activation inducible expression system in immune cells
EP4185388A1 (en) 2020-07-23 2023-05-31 Genmab B.V. A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
US20230310599A1 (en) 2020-09-02 2023-10-05 Genmab A/S Antibody therapy
BR112023001733A2 (pt) 2020-09-04 2023-03-28 Merck Patent Gmbh Anticorpos anti-ceacam5 e conjugados e usos dos mesmos
CN116670166A (zh) * 2020-12-07 2023-08-29 Ucb生物制药有限责任公司 多特异性抗体和抗体组合
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
EP4334359A1 (en) 2021-05-07 2024-03-13 Genmab A/S Pharmaceutical compositions comprising bispecific antibodies binding to b7h4 and cd3
IL308733A (en) 2021-05-27 2024-01-01 Sanofi Sa Fc variant with increased affinity for Fc receptors and improved thermal stability
KR20240029062A (ko) 2021-07-02 2024-03-05 메르크 파텐트 게엠베하 항-protac 항체 및 복합체
IL311062A (en) * 2021-08-20 2024-04-01 Neovacs Messenger RNA vaccines containing interleukin-4 and/or interleukin 13 RNA and their uses
TW202333797A (zh) 2021-11-05 2023-09-01 法商賽諾菲公司 含有抗ceacam5抗體-藥物接合物及抗vegfr-2抗體之抗腫瘤組合
WO2023130010A1 (en) 2021-12-30 2023-07-06 Regeneron Pharmaceuticals, Inc. Methods for attenuating atopic march by administering an il-4/il-13 antagonist
US20240117030A1 (en) * 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
WO2023170240A1 (en) 2022-03-09 2023-09-14 Merck Patent Gmbh Anti-ceacam5 antibodies and conjugates and uses thereof
EP4245772A1 (en) 2022-03-18 2023-09-20 Netris Pharma Anti-netrin-1 antibody to treat liver inflammation
EP4249509A1 (en) 2022-03-22 2023-09-27 Netris Pharma Anti-netrin-1 antibody against arthritis-associated pain
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
EP0362371A4 (en) 1988-04-15 1990-10-24 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
ES2070172T3 (es) 1988-04-16 1995-06-01 Celltech Ltd Procedimiento para producir proteinas mediante adn recombinante.
EP0428534B1 (en) 1988-06-14 1995-03-29 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
CA2018228C (en) 1989-06-05 1996-02-27 Nancy L. Parenteau Cell culture systems and media
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
CA2078689C (en) 1990-03-20 2003-02-11 Sherie L. Morrison Chimeric antibodies with receptor binding ligands in place of their constant region
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0574395B1 (en) 1990-11-09 2002-06-12 GILLIES, Stephen D. Cytokine immunoconjugates
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
EP0598877B1 (en) 1992-06-09 1999-07-28 Hoppe Ag Latch and lockset system
EP0749475A4 (en) 1992-08-26 1997-05-07 Harvard College USE OF THE CYTOKIN IP-10 AS AN ANTI-TUMOR AGENCY
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
UA40577C2 (uk) * 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
RU2162711C2 (ru) * 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
PL180125B1 (pl) 1993-09-07 2000-12-29 Smithkline Beecham Corp Bialko fuzyjne o swoistosci wiazania przeciwko ludzkiej IL-4, PL PL PL PL PL PL
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
WO1995009917A1 (en) * 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5597710A (en) 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
CN1173878A (zh) * 1995-10-16 1998-02-18 尤尼利弗公司 双功能或双价抗体片段类似物
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
CA2248868A1 (en) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
JPH11507843A (ja) 1996-03-28 1999-07-13 ザ・ジョンズ・ホプキンス・ユニバーシティー タンパク質の可溶性二価および多価ヘテロ二量体類縁体
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
GB9625899D0 (en) * 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ATE200679T1 (de) 1997-04-14 2001-05-15 Micromet Ag Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU753157B2 (en) 1997-11-03 2002-10-10 Georgetown University Medical Center VEGI, an inhibitor of angiogenesis and tumor growth
WO2000018435A1 (de) * 1998-09-25 2000-04-06 Horst Lindhofer Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
KR20120091477A (ko) * 1999-03-25 2012-08-17 애보트 게엠베하 운트 콤파니 카게 사람 ｉｌ-12에 결합하는 사람 항체 및 이의 제조방법
IL151853A0 (en) 2000-04-11 2003-04-10 Genentech Inc Multivalent antibodies and uses therefor
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
WO2001090192A2 (en) * 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
JP2004523205A (ja) * 2000-07-25 2004-08-05 イムノメディクス， インコーポレイテッド 多価標的結合タンパク質
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
RU2295537C2 (ru) * 2000-10-20 2007-03-20 Тугаи Сейяку Кабусики Кайся Модифицированное агонистическое антитело
US20040023338A1 (en) 2001-10-26 2004-02-05 Heavner George A. IL-4 mutein proteins, antibodies, compositions, methods and uses
EP1578912A4 (en) 2001-10-26 2007-12-26 Centocor Inc IL-13 MUTEIN PROTEINS, ANTIBODIES, COMPOSITIONS, METHODS AND USES
WO2003092610A2 (en) 2002-05-01 2003-11-13 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat hiv infection and aids
US20070104710A1 (en) * 2002-06-28 2007-05-10 Domants Limited Ligand that has binding specificity for IL-4 and/or IL-13
JP2006526408A (ja) 2003-04-22 2006-11-24 アイビーシー、ファーマシューティカルズ 多価タンパク質複合体
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
BRPI0416603A (pt) * 2003-11-07 2007-01-30 Immunex Corp anticorpo que se liga ao receptor interleucina-4 (il-4) humano
PT2805728T (pt) * 2003-12-23 2020-04-08 Genentech Inc Novos anticorpos anti-il13 e o uso dos mesmos
US7652146B2 (en) 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
ES2567634T3 (es) 2004-02-09 2016-04-25 Human Genome Sciences, Inc. Proteínas de fusión de albúmina
EP2026071B1 (en) 2004-02-19 2013-07-31 Yale University Identification of cancer protein biomarkers using proteomic techniques
AU2005219837A1 (en) 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. IL-4/IL-13 sepecific polypetides and therapeutic uses thereof
GB0411186D0 (en) * 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
MXPA06013709A (es) * 2004-05-25 2008-01-16 Attenuon Llc Ligandos fijadores del complejo activador de plasminogeno de tipo uroquinasa (upa) y su receptor (upar), que inhiben las interacciones de upar corriente abajo: identificacion y uso en diagnostico o en terapia.
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
GB0414799D0 (en) * 2004-07-01 2004-08-04 Glaxo Group Ltd Immunoglobulins
US20060148009A1 (en) 2004-10-12 2006-07-06 Xencor, Inc. Prediction and assessment of immunogenicity
TW200902555A (en) * 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
WO2006117910A1 (ja) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
GB0514319D0 (en) * 2005-07-13 2006-06-14 Secr Defence Antibodies for anthrax
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2623429C (en) 2005-09-30 2015-01-13 Medimmune Limited Interleukin-13 antibody composition
EP2532679B1 (en) * 2005-10-21 2017-04-12 Novartis AG Human antibodies against il13 and therapeutic uses
GB0600488D0 (en) * 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
TW200740843A (en) 2006-01-24 2007-11-01 Domantis Ltd Ligands that bind IL-4 and/or IL-13
EP2004691A1 (en) * 2006-03-22 2008-12-24 Apogenix GmbH Antibody specific for human il-4 for the treament of cancer
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2686014A1 (en) * 2011-03-16 2014-01-22 Sanofi Uses of a dual v region antibody-like protein
TWI679019B (zh) * 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
TW201628647A (zh) * 2014-06-27 2016-08-16 賽諾菲公司 抗－ｉｌ４－ｉｌ１３雙特異性抗體

Also Published As

Publication number Publication date
RS57060B1 (sr) 2018-05-31
TWI616206B (zh) 2018-03-01
CY1120887T1 (el) 2019-12-11
DK2205640T3 (en) 2014-02-24
BRPI0818677A2 (pt) 2015-04-14
EP2574630B1 (en) 2018-04-18
IL249289A0 (en) 2017-01-31
AU2013203324B2 (en) 2017-01-19
PT2205640E (pt) 2014-02-25
CR20150102A (es) 2015-04-30
CA3071750A1 (en) 2009-04-23
CN106986938A (zh) 2017-07-28
ES2447915T3 (es) 2014-03-13
PH12013501033B1 (en) 2015-05-25
US10759871B2 (en) 2020-09-01
LT2573121T (lt) 2017-12-11
PL2574629T3 (pl) 2018-05-30
EP2573116A1 (en) 2013-03-27
CA3071750C (en) 2022-06-14
KR101823859B1 (ko) 2018-02-01
DOP2010000109A (es) 2010-05-31
TW200932263A (en) 2009-08-01
TW201536321A (zh) 2015-10-01
NZ709353A (en) 2018-06-29
RS56553B1 (sr) 2018-02-28
PL2574630T3 (pl) 2018-09-28
JP2016006086A (ja) 2016-01-14
HUE038444T2 (hu) 2018-10-29
EP2574630A1 (en) 2013-04-03
NI201000404A (es) 2010-09-07
US20130236460A1 (en) 2013-09-12
AU2013203324A1 (en) 2013-05-02
RU2010119521A (ru) 2011-11-27
CN101827863A (zh) 2010-09-08
TR201802225T4 (tr) 2018-03-21
TR201810005T4 (tr) 2018-08-27
CY1120108T1 (el) 2018-12-12
AU2013203339B2 (en) 2017-01-05
DK2573119T3 (en) 2018-04-16
PL2205640T3 (pl) 2014-05-30
JP2018078907A (ja) 2018-05-24
RS53175B (en) 2014-06-30
AU2013203328B9 (en) 2017-02-02
IL205005A (en) 2016-11-30
ES2664476T3 (es) 2018-04-19
NZ729148A (en) 2021-12-24
HUE037205T2 (hu) 2018-08-28
TWI616205B (zh) 2018-03-01
SI2573121T1 (en) 2018-01-31
PA8799001A1 (es) 2009-07-23
MY171214A (en) 2019-10-02
US20130243776A1 (en) 2013-09-19
EP2573119A1 (en) 2013-03-27
EP2573121A1 (en) 2013-03-27
EP2205640B1 (en) 2013-11-20
US20130236463A1 (en) 2013-09-12
AR122833A2 (es) 2022-10-12
NI201000406A (es) 2010-09-07
TWI619508B (zh) 2018-04-01
RS56914B1 (sr) 2018-05-31
SG10201913836SA (en) 2020-03-30
PT2573121T (pt) 2017-11-21
RU2580049C2 (ru) 2016-04-10
WO2009052081A3 (en) 2009-06-04
RU2015141428A3 (es) 2019-04-30
HUE036530T2 (hu) 2018-07-30
AR122834A2 (es) 2022-10-12
JP6126653B2 (ja) 2017-05-10
NI201000403A (es) 2010-09-07
NI201000401A (es) 2010-09-07
JP2015231382A (ja) 2015-12-24
RU2488595C2 (ru) 2013-07-27
RU2705551C2 (ru) 2019-11-07
CL2013002039A1 (es) 2014-03-07
CN113480647A (zh) 2021-10-08
WO2009052081A2 (en) 2009-04-23
RU2015141418A3 (es) 2019-05-14
SG10201602770UA (en) 2016-05-30
EP2574626A1 (en) 2013-04-03
AU2013203339A1 (en) 2013-05-02
NI201000040A (es) 2010-09-07
NZ584658A (en) 2012-08-31
NI201000405A (es) 2010-09-07
EP2573117A1 (en) 2013-03-27
AU2013203328B2 (en) 2017-01-05
HRP20171765T1 (hr) 2017-12-29
AU2013202389A1 (en) 2013-05-02
US20140023649A1 (en) 2014-01-23
RU2013120318A (ru) 2014-11-10
US20130209469A1 (en) 2013-08-15
US20130251716A1 (en) 2013-09-26
RU2721236C2 (ru) 2020-05-18
BRPI0818677B8 (pt) 2021-05-25
US20130259866A1 (en) 2013-10-03
PE20091382A1 (es) 2009-10-14
SI2573119T1 (en) 2018-05-31
KR20160142889A (ko) 2016-12-13
CL2008003037A1 (es) 2009-03-06
PH12013501033A1 (en) 2015-05-25
KR20140112574A (ko) 2014-09-23
KR101954596B1 (ko) 2019-03-07
CA2702473A1 (en) 2009-04-23
EP2050764A1 (en) 2009-04-22
KR101681909B1 (ko) 2016-12-05
PL2573121T3 (pl) 2018-01-31
MX354150B (es) 2018-02-15
JP5858616B2 (ja) 2016-02-10
LT2573119T (lt) 2018-04-10
AU2013202389B2 (en) 2017-01-05
CR20150654A (es) 2016-02-08
AR068861A1 (es) 2009-12-09
US20130243777A1 (en) 2013-09-19
CY1119875T1 (el) 2018-06-27
JP2011501671A (ja) 2011-01-13
US11453727B2 (en) 2022-09-27
DK2574629T3 (en) 2018-02-26
EP2573121B1 (en) 2017-08-23
TW201536322A (zh) 2015-10-01
HN2010000710A (es) 2013-07-22
HRP20140150T1 (hr) 2014-03-28
CY1114987T1 (el) 2016-12-14
DK2574630T3 (en) 2018-07-30
AU2008312655B2 (en) 2013-05-02
RS57396B1 (sr) 2018-09-28
US9732162B2 (en) 2017-08-15
DOP2013000302A (es) 2014-02-16
HRP20180320T1 (hr) 2018-04-06
AU2013203328A1 (en) 2013-05-02
MX363638B (es) 2019-03-28
JP6280526B2 (ja) 2018-02-14
PL2573119T3 (pl) 2018-07-31
EP3686220A1 (en) 2020-07-29
EP2574629A1 (en) 2013-04-03
CA2702473C (en) 2018-10-09
ES2660152T3 (es) 2018-03-21
US20130236461A1 (en) 2013-09-12
ES2647872T3 (es) 2017-12-27
WO2009052081A4 (en) 2009-07-23
PH12013501032A1 (en) 2015-05-18
KR101682373B1 (ko) 2016-12-06
US20130251717A1 (en) 2013-09-26
AU2008312655A1 (en) 2009-04-23
CR11337A (es) 2010-04-21
GT201000067A (es) 2012-04-12
US20180030156A1 (en) 2018-02-01
SI2574630T1 (en) 2018-08-31
MA31838B1 (fr) 2010-11-01
SI2205640T1 (sl) 2014-04-30
KR20100067669A (ko) 2010-06-21
TW201825117A (zh) 2018-07-16
HRP20181085T1 (hr) 2018-09-07
US20210047437A1 (en) 2021-02-18
EP2205640A2 (en) 2010-07-14
EP2573119B1 (en) 2018-01-03
CR20150101A (es) 2015-04-14
RU2015141428A (ru) 2017-04-04
MX2010003290A (es) 2010-04-30
US20130251718A1 (en) 2013-09-26
KR20180014189A (ko) 2018-02-07
CR20150103A (es) 2015-04-14
KR20190022928A (ko) 2019-03-06
SI2574629T1 (en) 2018-03-30
US9738728B2 (en) 2017-08-22
JP6126652B2 (ja) 2017-05-10
CY1120033T1 (el) 2018-12-12
LT2574629T (lt) 2018-03-12
CN106986938B (zh) 2021-07-09
SG10201913838RA (en) 2020-03-30
EP2573118A1 (en) 2013-03-27
HRP20180517T1 (hr) 2018-05-04
CL2013002040A1 (es) 2014-01-24
JP2016006087A (ja) 2016-01-14
EP2573115A1 (en) 2013-03-27
US20100226923A1 (en) 2010-09-09
PT2574629T (pt) 2018-02-23
CL2012003196A1 (es) 2013-01-25
DK2573121T3 (en) 2017-12-04
CA3015470C (en) 2022-01-18
UA104130C2 (uk) 2014-01-10
NO2573121T3 (es) 2018-01-20
TN2010000126A1 (en) 2011-09-26
LT2574630T (lt) 2018-07-25
HUE038556T2 (hu) 2018-10-29
AU2013203339B9 (en) 2017-02-02
AU2013203324C1 (en) 2017-03-30
BRPI0818677B1 (pt) 2019-11-12
ZA201002069B (en) 2010-12-29
NZ601342A (en) 2014-02-28
MX354666B (es) 2018-03-15
EP2574629B1 (en) 2017-11-22
CN101827863B (zh) 2017-03-22
US20130243778A1 (en) 2013-09-19
ES2679281T3 (es) 2018-08-23
MX363901B (es) 2019-04-08
DOP2013000301A (es) 2014-02-16
MX363634B (es) 2019-03-28
UA118949C2 (uk) 2019-04-10
US8388965B2 (en) 2013-03-05
PH12013501032B1 (en) 2015-05-18
RU2015141418A (ru) 2017-04-04
US20230235088A1 (en) 2023-07-27
PT2574630T (pt) 2018-07-17
SG185303A1 (en) 2012-11-29
NO2574629T3 (es) 2018-04-21
NI201000402A (es) 2010-09-07
PT2573119T (pt) 2018-04-04
IL205005A0 (en) 2010-11-30
US20130236462A1 (en) 2013-09-12
CA3015470A1 (en) 2009-04-23
AU2013202389B9 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
AR122834A2 (es) Anticuerpos que se unen a il-4 y/o il-13 y sus usos
ECSP12011879A (es) Anticuerpo anti-tslp modificado por técnicas de ingeniería genética
CR11152A (es) Metodos y composiciones para el tratamiento de enfermedades alergicas
PA8775101A1 (es) Anticuerpos anti-ige
CL2013002743A1 (es) Cristal de anticuerpo de igg anti-esclerostina; metodo de produccion; composicion que lo comprende; y su uso para tratar desordenes oseos.
UY32060A (es) Anticuerpos anti-il-13 obtenidos mediante ingeniería, composiciones , métodos y usos
UY32489A (es) Moléculas de anticuerpos que tienen especificidad de unión por il-13 humana
ECSP12012202A (es) Anticuerpos il-25 humanizados

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20200730